← Database
M&A

WINBACK

Acquired by

CHARTERHOUSE

FRANCE Life Sciences EV [100m EUR - 500m EUR] 12/2025

Target

WINBACK

Acquirer

CHARTERHOUSE

Context

Charterhouse Capital Partners acquired a majority equity stake in Winback following a competitive process that attracted interest from several top-tier private equity funds. This transaction facilitates the exit of Capza, which had supported the company since late 2021 through a minority "flex equity" structure, and allows the founding duo to cash out a portion of their holdings while reinvesting to remain significant minority shareholders and operational leaders. The deal is financed through a combination of equity and a debt package comprising senior bank debt provided by a consortium of French banks and a mezzanine tranche arranged by a specialized private debt fund. The new partnership is intended to drive the next phase of growth, focusing on deepening market penetration in existing territories and expanding the product portfolio.

WINBACK, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a level LOGIN the 13.4x average currently observed in the Healthcare & Pharma sector.

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2013, Winback is a high-growth French medical technology company specializing in the design, manufacturing, and distribution of advanced devices for tissue rehabilitation and pain management. The company has built its reputation on TECAR technology (Transfer of Energy Capacitive and Resistive), utilizing high-frequency currents to accelerate the body's natural regeneration processes. Beyond its core radiofrequency solutions, Winback has diversified its portfolio to include cryotherapy and compression systems. Its devices are essential tools for a wide range of practitioners, including physiotherapists, osteopaths, and sports doctors, with applications extending to chronic pain treatment, women's post-partum health, and aesthetic medicine.

Ent. Value

LOGIN

Equity Value

LOGIN

Multiples Analysis

EV / Revenue

LOGIN

EV / EBITDA

LOGIN

EV / EBIT

LOGIN

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2024
LOGIN
LOGIN
LOGIN
2023
LOGIN
LOGIN
LOGIN

Other operations with WINBACK

mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.